Storm Clouds Over the Horizon in Orthopedics?
A decade ago, the threat of price and margin pressure never materialized for orthopedics companies. Instead, the industry entered a prolonged period of strong pricing, aggressive new technology adoption, and widespread investor support. But some industry observers wonder how long the good times, particularly as expressed by strong pricing, can last, as the gulf between orthopedics suppliers' profits and those of their customers widen. Perhaps even more worrisome: Justice Department investigations into off-label use and how suppliers pay surgeons could seriously disrupt the industry by calling into question long-established practices.
You may also be interested in...
Across a wide range of specialties, the unique features of minimally invasive surgery provides a consistent array of beneifts to patients, and orthopedic surgeons have worked hard over the past several years to reduce the size of incisions in hip and knee replacement. Skeptics argue that, given the extremely high success rates of conventional hip and knee replacement surgery, any movement toward MIS should be slow and should look beyond patient appeal to focus on long-term results. For MIS leader Zimmer, the bet on the new technique is a big one. The widespread adoption of MIS in orthopedics is less about the transformation of a procedure than about the transformation of a company and an industry.
For the past year, hospital purchasing groups have been under a spotlight, as Senate investigators and major media investigate charges that groups have done more harm than good in favoring large product companies. One of two groups at the center of the crisis, Premier, says it is cleaning up its act-and even hired an ethicist to help-but its take on necessary reforms embraces a broad, big-picture view of hospital/GPO relationships. MedAssets is taking more of a back-to-basics approach that stresses flexibility and choice in contracting options while helping members address the escalating costs of physician preferred products. The challenge for GPOs: the pressure to reform comes at a time when competition for hospital customers is fierce, in part because the financial pressure on hospitals has never been greater.
Drawing on 24 years as a legislator and another 16 years as a leading lobbyist for biopharma, Jim Greenwood sees an opportunity for industry to put drug pricing ‘behind us’ with a legislative compromise.